These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 12741621

  • 1. Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo.
    Fischer M, Trkola A, Joos B, Hafner R, Joller H, Muesing MA, Kaufman DR, Berli E, Hirschel B, Weber R, Günthard HF, Swiss HIV-1 Cohort Study.
    Antivir Ther; 2003 Apr; 8(2):97-104. PubMed ID: 12741621
    [Abstract] [Full Text] [Related]

  • 2. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.
    N Engl J Med; 1999 May 27; 340(21):1614-22. PubMed ID: 10341273
    [Abstract] [Full Text] [Related]

  • 3. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
    Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Günthard HF, Swiss HIV Cohort Study.
    J Infect Dis; 2004 Dec 01; 190(11):1979-88. PubMed ID: 15529263
    [Abstract] [Full Text] [Related]

  • 4. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts.
    Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, Hirschel B, Trkola A, Kuster H, Weber R, Günthard HF, Swiss HIV Cohort Study.
    Antivir Ther; 2002 Jun 01; 7(2):91-103. PubMed ID: 12212929
    [Abstract] [Full Text] [Related]

  • 5. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo.
    Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM.
    Virology; 1994 Dec 01; 205(2):470-8. PubMed ID: 7975248
    [Abstract] [Full Text] [Related]

  • 6. [Non conventional virological markers in HIV-infected patients: T-HIV DNA, 2LTR-HIV DNA and HIV RNA].
    Gariglio R, Taborda MA, Bortolozzi R, McDermott JL, Martini I, Borgognone M, Villanova GV, Varnier OE, Giri AA.
    Medicina (B Aires); 2004 Dec 01; 64(5):419-28. PubMed ID: 15560543
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
    Derdeyn CA, Kilby JM, Miralles GD, Li LF, Sfakianos G, Saag MS, Hockett RD, Bucy RP.
    J Infect Dis; 1999 Dec 01; 180(6):1851-62. PubMed ID: 10558941
    [Abstract] [Full Text] [Related]

  • 8. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.
    Cara A, Vargas J, Keller M, Jones S, Mosoian A, Gurtman A, Cohen A, Parkas V, Wallach F, Chusid E, Gelman IH, Klotman ME.
    Virology; 2002 Jan 05; 292(1):1-5. PubMed ID: 11878902
    [Abstract] [Full Text] [Related]

  • 9. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, Prins JM, Schuitemaker H.
    Antivir Ther; 2003 Apr 05; 8(2):137-42. PubMed ID: 12741626
    [Abstract] [Full Text] [Related]

  • 10. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM, Cheney KM, Coolen C, Davis A, Shaw D, Ferguson W, Chang G, Higgins G, Burrell C, Li P.
    J Clin Microbiol; 2007 Apr 05; 45(4):1288-97. PubMed ID: 17314225
    [Abstract] [Full Text] [Related]

  • 11. Different patterns of HIV-1 DNA after therapy discontinuation.
    Re MC, Vitone F, Sighinolfi L, Schiavone P, Ghinelli F, Gibellini D.
    BMC Infect Dis; 2005 Sep 12; 5():69. PubMed ID: 16156892
    [Abstract] [Full Text] [Related]

  • 12. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML, French PRIMO Cohort Study Group (ANRS CO 06).
    AIDS; 2006 Jan 09; 20(2):159-70. PubMed ID: 16511408
    [Abstract] [Full Text] [Related]

  • 13. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G, Abbate I, D'Offizi G, Corpolongo A, Narciso P, Vlassi C, Martini F, Calcaterra S, Capobianchi MR.
    J Med Virol; 2007 Aug 09; 79(8):1047-54. PubMed ID: 17597482
    [Abstract] [Full Text] [Related]

  • 14. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C, Gourlain K, Tubiana R, Carcelain G, Marcelin AG, Chouquet C, Mouroux M, Duvivier C, Autran B, Costagliola D, Katlama C, Calvez V.
    Antivir Ther; 2003 Jun 09; 8(3):233-7. PubMed ID: 12924540
    [Abstract] [Full Text] [Related]

  • 15. Relationship between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1-infected children initiating antiretroviral therapy.
    De Rossi A, Walker AS, De Forni D, Klein N, Gibb DM, Paediatric European Network for Treatment of AIDS.
    Antivir Ther; 2005 Jun 09; 10(1):63-71. PubMed ID: 15751764
    [Abstract] [Full Text] [Related]

  • 16. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 17. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
    Usuku S, Noguchi Y, Sakamoto M, Adachi T, Sagara H, Sudo K, Nishizawa M, Kondo M, Tochikubo O, Imai M.
    Jpn J Infect Dis; 2006 Apr 20; 59(2):122-5. PubMed ID: 16632914
    [Abstract] [Full Text] [Related]

  • 18. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
    Pellegrin I, Thiébaut R, Blanco P, Viallard JF, Schrive MH, Merel P, Chêne G, Fleury H, Moreau JF, Pellegrin JL.
    J Med Virol; 2005 Oct 20; 77(2):164-72. PubMed ID: 16121362
    [Abstract] [Full Text] [Related]

  • 19. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palù G.
    J Clin Microbiol; 2007 Jun 20; 45(6):1783-8. PubMed ID: 17442799
    [Abstract] [Full Text] [Related]

  • 20. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
    Vitone F, Gibellini D, Schiavone P, Re MC.
    J Clin Virol; 2005 Jul 20; 33(3):194-200. PubMed ID: 15911440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.